stars 1 stars 2 stars 3

IGEA studies the clinical application of physical stimuli to biological systems. Our mission is to improve patients’ quality of life by developing and producing innovative, effective and safe therapeutic systems for clinical practice. IGEA develops biophysical treatments in two main areas: - Orthopedics: to improve bone healing and joint preservation. - Oncology: to treat cancer. IGEA is the world leading company for Electrochemotherapy, a minimally invasive treatment combining a low dose of a chemotherapy drug and electrical pulses (electroporation) applied directly to the cancer cells using specific multiple or individual electrodes. Cliniporator® and Cliniporator® VITAE are the most advanced electroporation technologies for the treatment of tumor nodules located to the skin, subcutaneous tissue, parenchyma and bone.

IGEA S.p.A. Questions

The IGEA S.p.A. annual revenue was $13.3 million in 2026.

7 people are employed at IGEA S.p.A..

Top IGEA S.p.A. Employees

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users